Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology Surging
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com